Skip to main content
BIOBIJOU Co., Ltd. logo

BIOBIJOU Co., Ltd. — Investor Relations & Filings

Ticker · 489460 ISIN · KR7489460006 KO Manufacturing
Open in API
Filings indexed 29 across all filing types
Latest filing 2026-04-17 Regulatory Filings
Country KR South Korea
Listing KO 489460

About BIOBIJOU Co., Ltd.

http://www.biobijou.co.kr/eng/

BIOBIJOU Co., Ltd. is a biotechnology company that researches, develops, manufactures, and distributes medical aesthetic and healthcare products. The company's portfolio primarily consists of hyaluronic acid (H.A.)-based dermal fillers, injectable skin boosters, fat-dissolving solutions, and a range of cosmetic skincare items. BIOBIJOU operates across the entire value chain, from initial product development to global sales, employing automated production facilities and rigorous quality control systems. The company serves a global market, with an established international sales network and a significant distribution presence in China. It focuses on technological research and development to provide stable and high-quality products for the skincare and wellness sectors.

Recent filings

Filing Released Lang Actions
기업가치제고계획(자율공시)
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate value enhancement plan (“기업가치 제고 계획(자율공시)”) containing forward‐looking business targets, R&D and dividend policy details. It is not an earnings release (no financial results), not a board or management change notice, not a specific financing or share issuance, nor any other narrowly defined category. It is a general regulatory disclosure made under Korean voluntary disclosure rules and therefore falls into the fallback category ‘Regulatory Filings’.
2026-04-17 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is the official result of a regular shareholders’ meeting (AGM) held on March 31, 2026, showing detailed agenda items, vote counts, approval status for financial statements, dividends, director and auditor appointments, and vote percentages. This corresponds to a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-03-31 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is titled “감사보고서 제출” (Submission of Audit Report) and contains auditor’s opinions on consolidated and separate financial statements, key financial metrics, the auditor’s name, and the audit report receipt date. It does not include a full annual report format or investor presentation, nor is it merely a notice of publication. It is a standalone audit report submission. Therefore, it fits the Audit Report / Information category. FY 2025
2026-03-23 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 8th fiscal year (2025), submitted to the Financial Services Commission and the Korea Exchange. It contains comprehensive financial data, business descriptions, management information, and governance details. This is the standard format for an annual financial report in South Korea, which corresponds to the 10-K filing type in the provided schema. FY 8
2026-03-23 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for BioBijou. It contains the agenda for the upcoming Annual General Meeting (AGM), including reports on financial statements, dividend proposals, and board/auditor appointments. It also includes detailed financial statements (balance sheet, income statement, etc.) as part of the 'Management Reference' (경영참고사항) required for shareholder review prior to the meeting. This document is a standard proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes.
2026-03-16 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (BioBijou) disclosing a significant change (over 30%) in revenue or profit structure compared to the previous fiscal year. This is a standard mandatory disclosure filing in the Korean market (DART system) regarding financial performance fluctuations. Since it provides the actual financial data and the reasons for the change rather than just announcing the publication of a report, it is classified as an Earnings Release (ER) equivalent in the context of the provided categories. FY 2025
2026-03-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.